A Single-Center, Randomized, Investigator/Subject-Blind, Multiple Ascending-Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5508887 Following Oral Administration in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Sep 2015
Price : $35 *
At a glance
- Drugs RG 7129 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Biomarker
- Sponsors Roche
- 19 Feb 2013 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
- 03 Jan 2013 Planned end date changed from 1 May 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 18 Oct 2012 Planned End Date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.